(Professor of Medicine, Hematology-Oncology Division, Beth Israel Deaconess Medical Center; 199 publications in PubMed)
He is director of training and mentoring at the Beth Israel Deaconess Medical Center Cancer Research Institute, and co-director of the Dana Farber/Harvard Cancer Center Prostate Cancer Specialized Program of Research Excellence (SPORE). Dr. Balk has a broad interest in understanding the molecular basis of prostate cancer development and progression in order to identify new therapies for prevention and treatment. The Balk Lab also has projects related to androgen receptor (AR), SOX9, WNT signaling, and apoptotic pathways in prostate cancer. Studies in the Balk Lab employ cell line and mouse models, patient derived xenografts, and clinical samples from patients on clinical trials.